BioCentury
ARTICLE | Clinical News

VenatoRx reports preclinical data for VNRX-5133 plus cefepime

April 27, 2018 7:25 PM UTC

VenatoRx Pharmaceuticals Inc. (Malvern, Pa.) reported preclinical data from a mouse model of cephalosporin-resistant Klebsiella pneumoniae lung infection showing that VNRX-5133 plus the cephalosporin antibiotic cefepime led to greater reductions in mean bacterial lung titers compared with cefepime alone. Data were presented at the European Congress of Clinical Microbiology and Infectious Diseases in Madrid...

BCIQ Company Profiles

Venatorx Pharmaceuticals Inc.

BCIQ Target Profiles

Beta lactamase (LACTB)